Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Sep 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying new ways to detect pancreatic cancer, specifically a type called pancreatic ductal adenocarcinoma (PDAC). The researchers want to find out if measuring a substance called elastase-1, along with other common tests and imaging techniques like endoscopic ultrasonography (a special type of ultrasound), can help identify pancreatic cancer earlier and more accurately. They are particularly focused on high-risk individuals, such as those with a family history of the disease or other pancreatic conditions. The goal is to develop a reliable method for diagnosing this cancer to improve treatment options for patients.

To participate in the study, individuals should be between 65 and 74 years old and may include those diagnosed with pancreatic cancer, those at high risk for developing it, and patients with certain other pancreatic diseases. People who do not have pancreatic disease and have normal test results may also be included as a comparison group. Participants will undergo various tests, and researchers will analyze their blood and tissue samples to look for new markers that could help in diagnosis. It’s important to note that individuals younger than 18, those without a confirmed diagnosis of pancreatic disease, or those who haven’t signed consent cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Case groups (matching any of the following):
• • 1. Patients with pancreatic cancer with recognized diagnostic criteria or conclusions.
• • 2. Patients who are the high-risk group of pancreatic cancer.
• • 3. Patients with solid pseudo papilloma and neuroendocrine tumors of pancreas with recognized diagnostic criteria or conclusions.
• • 4. Patients with other diseases with abnormally elevated CA19-9.
• Control group:
• • (1) Patients without pancreatic disease assessed by laboratory tests and imaging examinations have no CA19-9 elevation.
• Exclusion Criteria:
• • 1. Patients who are younger than 18 years of age.
• • 2. Patients with suspected pancreatic malignant lesions but has no confirmed imaging or pathological diagnosis.
• • 3. Patients who have not signed informed consent.